Načítá se...
New agents and regimens for diffuse large B cell lymphoma
As a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large B cell lymphoma (DLBCL), and the remaining patients suffer from refractory or relapsed disease due to resistance to R-CHO...
Uloženo v:
| Vydáno v: | J Hematol Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7734862/ https://ncbi.nlm.nih.gov/pubmed/33317571 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-01011-z |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|